Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 113 Breast Neoplasms 113 Ovarian Neoplasms 69 Triple Negative Breast Neoplasms 56 Endometrial Neoplasms 42 Fallopian Tube Neoplasms 40 Squamous Cell Carcinoma of Head and Neck 39 Lung Neoplasms 38 Neoplasm Metastasis 35 Stomach Neoplasms 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Neoplasms 27 Esophageal Neoplasms 22 Esophageal Squamous Cell Carcinoma 21 Head and Neck Neoplasms 16 Uterine Cervical Neoplasms 15 Carcinoma, Ovarian Epithelial 15 Carcinoma 15 Colorectal Neoplasms 14 Carcinoma, Squamous Cell 11 Adenocarcinoma 10 Small Cell Lung Carcinoma 9 Adenocarcinoma Of Esophagus 9 Peritoneal Neoplasms 8 Oropharyngeal Neoplasms 8 Melanoma 8 Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 7 Pancreatic Neoplasms 7 Mouth Neoplasms 7

Interventions

pembrolizumab 2 poly(I).poly(c12,U) 1 liposomal doxorubicin 1 Platinum Compounds 1 Paclitaxel 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Paclitaxel × 1 year × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡